Use filters to refine the search results.
Results 1-4 of 4
|20-May-2015||Final results of ProGem1, the first in-human phase I/II study of NUC-1031 in patients with solid malignancies||Blagden, SP; Rizzuto, I; Stavraka, C; O'Shea, D; Suppiah, P, et al|
|20-May-2015||A first in human Phase I/II study of NUC-1031 in patients with advanced gynecological cancers||Blagden, SP; Rizzuto, I; Stavraka, C; O'Shea, D; Suppiah, P, et al|
|20-May-2015||Homologous recombination (HR) deficiency, tumor BRCA1/2 mutations (tmBRCA) and association with response and outcome following platinum monotherapy in high grade serous ovarian cancer (HGSOC).||Brown, R; Timms, K; Paul, J; Hughes, E; El-Bahrawy, M, et al|
|1-Aug-2015||Preliminary results from PiSARRO, a phase Ib/II study of APR-246, a mutant p53 reactivating small molecule, in combination with standard chemotherapy in platinum-sensitive ovarian cancer||Von Euler, M; Wiman, KG; Gabra, H; Brenton, JD; Basu, B, et al|